



Flexion Therapeutics, Inc.
 Investor Relations Department
 10 Mall Road
 Suite 301
 Burlington, MA 01803
 United States

Visit IR website [↗](#)
 Sign-up for Email alerts [↗](#)

NASDAQ: FLXN

Last Trade:	26.56
Trade Time:	4:00 PM ET Apr 26, 2018
Change:	1.39 ▲ (+5.522%)
Day Range	25.11 - 26.68
52-Week Range	16.51 - 32.25
Volume	540,490


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Flexion is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA).

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Apr 26, 2018
[Flexion Therapeutics Presents Updated Results from Clinical Trial Evaluating Repeat Administration of ZILRETTA® \(triamcinolone acetonide extended-release injectable suspension\) at Osteoarthritis Research Society International World Congress](#)

Apr 24, 2018
[Flexion Therapeutics to Present Data on ZILRETTA® \(triamcinolone acetonide extended-release injectable suspension\) at the Academy of Managed Care Pharmacy Annual Meeting 2018](#)

Apr 18, 2018
[Flexion Therapeutics Announces Publication of Results from Pivotal Phase 3 Study of ZILRETTA® \(triamcinolone acetonide extended-release injectable suspension\) in the Journal of Bone and Joint Surgery](#)

Apr 6, 2018
[Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635\(c\)\(4\)](#)

Mar 19, 2018
[Flexion Therapeutics to Present at Needham & Company's 17th Annual Healthcare Conference](#)

Financials [\[View all \]](#)

[Fourth Quarter Financial Results](#)

Mar 8, 2018
[Annual Report \(10-K\)](#)

Apr 28, 2017
[Proxy Statement \(DEF 14A\)](#)

Nov 6, 2017
[Quarterly Report \(10-Q\)](#)

Aug 8, 2017
[Quarterly Report \(10-Q\)](#)

May 5, 2017
[Quarterly Report \(10-Q\)](#)

